Status:
COMPLETED
Hs-CRP as Clinical Marker of Inflammatory Atherogenic Dyslipidemia
Lead Sponsor:
CHU de Quebec-Universite Laval
Collaborating Sponsors:
AstraZeneca
Conditions:
Dyslipidemia
Eligibility:
All Genders
18-75 years
Brief Summary
The objective of this proposal is to study the applicability of the hs-CRP assay in the assessment of CV risk in daily clinical conditions where hyperlipidemic population with or without CHD are curre...
Detailed Description
Coronary heart disease (CHD) is the major cause of death in the developed world. Cholesterol screening has been used as a tool to identify individuals who are at increased risk of developing future co...
Eligibility Criteria
Inclusion
- metabolically stable in the last 3 months for weight (+/- 1 kg), lipid profile (+/- 15 % variability), infection (no symptoms for viral or bacterial illness), inflammation (absence of nonspecific symptoms for arthritis, normal blood sedimentation and protein electrophoresis for acute phase reactants) and no change of usual habits (ex. diet/exercise) or medications (ex. drugs)
- CHD patients will have to be stable (based on cardiac symptoms and ECG) during the last 3 months and diabetic patients will be required to have stable glycemia (HbA1c \< 7,5 %) in the last 6 months.
Exclusion
- history of drug or alcohol abuse
- uncontrolled liver, thyroid or kidney functions
- other drugs known to affect lipid levels or insulin resistance (antiprotease inhibitors, oral contraceptives...)
Key Trial Info
Start Date :
March 1 2005
Trial Type :
OBSERVATIONAL
End Date :
December 1 2006
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00169871
Start Date
March 1 2005
End Date
December 1 2006
Last Update
April 23 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lipid Research Center, CHUL Research Center
Sainte-Foy, Quebec, Canada, G1V 4G2